Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
LHDX - Lucira Health, Inc.
Market Cap 18.36M P/E - EPS this Y - Ern Qtrly Grth -
Income -143.28M Forward P/E -0.94 EPS next Y - 50D Avg Chg 26.00%
Sales 212.13M PEG - EPS past 5Y - 200D Avg Chg -62.00%
Dividend N/A Price/Book 0.30 EPS next 5Y 9.80% 52W High Chg -90.00%
Recommedations 3.00 Quick Ratio 0.72 Shares Outstanding 40.60M 52W Low Chg 319.00%
Insider Own 10.13% ROA -41.80% Shares Float 30.26M Beta 3.76
Inst Own 23.90% ROE -112.43% Shares Shorted/Prior 676.85K/1.21M Price 0.45
Gross Margin -18.48% Profit Margin -67.54% Avg. Volume 21,451,802 Target Price 0.50
Oper. Margin -64.94% Earnings Date May 10 Volume 36,259,018 Change 0.00%
Healthcare | Medical Devices | United States
About Lucira Health, Inc.

Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California. On February 22, 2023, Lucira Health, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Lucira Health, Inc. News
03/10/23 FDA Addresses 'Misinformation' Concerning Delayed Approval Of Lucira Health's COVID-19 & Flu Home Test
02/27/23 FDA Approval Brings Some Good News For Bankrupt Lucira Health
02/27/23 UPDATE 1-Lucira's home test for flu and COVID-19 gets U.S. FDA nod for OTC use
02/27/23 Lucira Health Announces FDA Authorization of First & Only At-Home Combination Covid-19 & Flu Test and Comments on Chapter 11 Bankruptcy Filing
02/24/23 Lucira stock more than doubles after hours on FDA OK for COVID-19, flu test
05:01 PM At-home Covid test maker falls into Chapter 11 bankruptcy
11:15 AM Within Two Years Of Public Debut, COVID-19 Test Maker Files For Bankruptcy
02/22/23 Lucira Health files for bankruptcy, will pursue sale
02/22/23 Covid Test Maker Lucira Goes Bankrupt as Demand for Kits Wanes
02/22/23 Lucira Health to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
02/02/23 The Zacks Analyst Blog Highlights AppHarvest, Lucira Health, Lucid Group, Life Time Group and Ameriprise Financial
02/01/23 5 Big Winners as Wall Street Wraps Up Strong January Gains
01/05/23 SESAME PARTNERS WITH LUCIRA HEALTH AS OFFICIAL TELEHEALTH PROVIDER OF LAB-QUALITY TEST-TO-TREAT PROGRAM
01/04/23 As EU works to coordinate response to China’s COVID wave, Beijing and airlines are unhappy
01/04/23 Lucira Health Launches Lucira Connect, a Free Test-to-Treat Telehealth Service for Covid-19 or Flu in Canada
01/03/23 Lucira Health Submits EUA for Over-The-Counter (OTC) Use of its COVID-19 & Flu Test
12/21/22 Skillz, Grove Collaborative and Lucira Health receive delisting notices
12/06/22 Lucira and Loch Lomond Villa Announce Clinical Study to Tackle Tripledemic With First and Only Combination COVID-19 and Flu OTC Molecular Self-Test
11/22/22 Lucira Health Announces FDA Authorization of Combination COVID-19 & Flu Test at Point-of-Care
11/17/22 Lucira Health Announces National Launch of Lucira Connect Test-to-Treat Service
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Engelson Erik T. President and Chief.. President and Chief Executive Mar 03 Sell 1.06 634,666 672,746 23,282 03/13/23
Engelson Erik T. President and Chief.. President and Chief Executive Mar 03 Option 0.82 574,666 471,226 657,948 03/13/23
Narido Richard Clavano Chief Financial Offi.. Chief Financial Officer Mar 03 Sell 0.85 29,383 24,976 77,910 03/13/23
Collins Kevin Walter Chief Revenue Office.. Chief Revenue Officer Mar 03 Sell 0.82 111,819 91,692 234,903 03/13/23
Allen Anthony Joseph Chief Operations Off.. Chief Operations Officer Mar 03 Sell 1.00 8,405 8,405 136,520 03/13/23
Kashmolah Ghazi Ex VP & Chief Qualit.. Ex VP & Chief Quality Officer Feb 16 Sell 0.27 5,028 1,358 134,075 02/21/23
Allen Anthony Joseph Chief Operations Off.. Chief Operations Officer Dec 20 Sell 0.16 4,263 682 144,925 12/22/22
Collins Kevin Walter Chief Revenue Office.. Chief Revenue Officer Nov 27 Sell 0.42 9,666 4,060 346,722 11/29/22
Kashmolah Ghazi Ex VP & Chief Qualit.. Ex VP & Chief Quality Officer Nov 16 Sell 0.35 4,790 1,676 179,887 11/18/22
Engelson Erik T. President and Chief.. President and Chief Executive Sep 15 Buy 1.82 20,000 36,400 83,282 09/19/22
Mitra Debkishore Chief Technology Off.. Chief Technology Officer Sep 01 Sell 1.694 191 324 382,208 09/06/22
Collins Kevin Walter Chief Revenue Office.. Chief Revenue Officer Aug 27 Sell 1.72 8,580 14,758 356,388 08/29/22
Kashmolah Ghazi Ex VP & Chief Qualit.. Ex VP & Chief Quality Officer Aug 25 Sell 1.93 1,500 2,895 184,677 08/29/22
Kashmolah Ghazi Ex VP & Chief Qualit.. Ex VP & Chief Quality Officer Aug 17 Sell 2.52 19,074 48,066 180,757 08/24/22
Mitra Debkishore Chief Technology Off.. Chief Technology Officer Mar 01 Sell 3.27 1,076 3,519 382,399 07/12/22
Prashar Tamanna Vice President Vice President Mar 01 Sell 3.02 1,794 5,418 117,394 07/12/22
Collins Kevin Walter Chief Revenue Office.. Chief Revenue Officer May 27 Sell 2.00 37,109 74,218 364,968 07/12/22
George Dan CFO and Treasurer CFO and Treasurer Jun 18 Sell 1.45 1,321 1,915 46,354 07/12/22
Engelson Erik T. President and Chief.. President and Chief Executive Jun 16 Buy 1.49 10,000 14,900 63,282 06/17/22
Engelson Erik T. President and Chief.. President and Chief Executive Mar 15 Buy 3.00 30,000 90,000 53,282 03/16/22